OPKO Health holders back 2026 meeting proposals

OPKO Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026.

Rhea-AI Filing Summary

OPKO Health, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected eleven directors, each receiving more votes "For" than "Against", including Phillip Frost, M.D. with 423,666,978 votes for and 40,175,942 against.

Stockholders approved the Company’s 2026 Equity Incentive Plan, with 440,096,997 votes for and 23,694,041 against. They also approved, on a non-binding advisory basis, the compensation of the named executive officers, with 446,238,170 votes for and 17,487,326 against.

In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 535,070,921 votes for and 6,120,699 against. No other matters were considered or voted upon at the meeting.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Director votes – Phillip Frost: 423,666,978 For; 40,175,942 Against Equity Incentive Plan approval: 440,096,997 For; 23,694,041 Against Say-on-pay advisory vote: 446,238,170 For; 17,487,326 Against +3 more

6 metrics

Director votes – Phillip Frost 423,666,978 For; 40,175,942 Against Election of directors at 2026 Annual Meeting

Equity Incentive Plan approval 440,096,997 For; 23,694,041 Against 2026 Equity Incentive Plan stockholder vote

Say-on-pay advisory vote 446,238,170 For; 17,487,326 Against Non-binding vote on executive compensation

Auditor ratification 535,070,921 For; 6,120,699 Against Ernst & Young LLP ratified for FY ending Dec. 31, 2026

Equity Plan broker non-votes 79,767,645 Broker non-votes on 2026 Equity Incentive Plan proposal

Say-on-pay broker non-votes 79,767,645 Broker non-votes on advisory compensation proposal

Key Terms

broker non-votes, 2026 Equity Incentive Plan, non-binding advisory basis, independent registered public accounting firm, +1 more

5 terms

broker non-votes financial

"Each director election line item lists For, Against, Abstain, and Broker Non-Votes."

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

2026 Equity Incentive Plan financial

"The stockholders voted to approve the Company’s 2026 Equity Incentive Plan as disclosed in the Company’s 2026 Proxy Statement."

non-binding advisory basis regulatory

"The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers."

A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.

independent registered public accounting firm regulatory

"The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Annual Meeting of Stockholders financial

"OPKO Health, Inc. held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OPKO Health (OPK) stockholders decide at the 2026 annual meeting?

Stockholders elected eleven directors and approved all major proposals. They backed the 2026 Equity Incentive Plan, supported executive compensation on an advisory basis, and ratified Ernst & Young LLP as auditor for the 2026 fiscal year.

Did OPKO Health (OPK) stockholders approve the 2026 Equity Incentive Plan?

Yes, stockholders approved the 2026 Equity Incentive Plan with 440,096,997 votes for and 23,694,041 against. This plan was described in the company’s 2026 proxy statement for the annual meeting and governs future equity-based compensation.

How did OPKO Health (OPK) stockholders vote on executive compensation?

On a non-binding advisory basis, stockholders approved named executive officer compensation with 446,238,170 votes for and 17,487,326 against. This say-on-pay vote reflects current shareholder support for the disclosed compensation program and practices.

Who is OPKO Health’s (OPK) independent auditor for fiscal year 2026?

Stockholders ratified Ernst & Young LLP as OPKO Health’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 535,070,921 votes for and 6,120,699 against, and 2,715,188 abstentions recorded.

Were all OPKO Health (OPK) director nominees elected at the 2026 meeting?

All eleven director nominees were elected, each receiving more votes for than against. For example, Phillip Frost, M.D. received 423,666,978 votes for and 40,175,942 against, with additional broker non-votes reported on the director election items.

Were there any other matters voted on at OPKO Health’s 2026 annual meeting?

No, only four proposals were considered: election of directors, approval of the 2026 Equity Incentive Plan, advisory approval of executive compensation, and auditor ratification. The company reported that no other matters were submitted for stockholder vote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:06 PM EDT Learn about SEC filing dates

0000944809false00009448092026-06-182026-06-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2026

OPKO Health, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33528	75-2402409
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4400 Biscayne Blvd.
Miami, Florida				33137
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 305 575-4100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		OPK		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 18, 2026, OPKO Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting and the corresponding votes.

1. All eleven nominees were elected to the Board of Directors with each director receiving votes as follows:

Election of Directors		For		Against		Abstain		Broker Non-Votes
Phillip Frost, M.D.		423,666,978		40,175,942		296,243		79,767,645
Jane H. Hsiao, Ph.D.		422,928,151		40,947,325		263,687		79,767,645
Elias A. Zerhouni, M.D.		420,402,573		42,561,617		1,174,973		79,767,645
Steven D. Rubin		409,356,877		54,519,219		263,067		79,767,645
Gary J. Nabel, M.D., Ph.D.		420,083,341		43,643,796		412,026		79,767,645
Prem A. Lachman, M.D.		428,600,587		35,002,548		536,028		79,767,645
Roger J. Medel, M.D.		428,125,427		35,411,814		601,922		79,767,645
John A. Paganelli		398,032,505		65,734,019		372,639		79,767,645
Richard C. Pfenniger, Jr.		424,416,857		39,352,175		370,131		79,767,645
Subbarao V. Uppaluri, Ph.D.		454,992,813		8,481,656		664,694		79,767,645
Alice Lin-Tsing Yu, M.D., Ph.D.		418,457,740		45,287,103		394,320		79,767,645

2. The stockholders voted to approve the Company’s 2026 Equity Incentive Plan as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

For		Against		Abstain		Broker Non-Votes
440,096,997		23,694,041		348,125		79,767,645

3. The stockholders voted to approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company as disclosed in the Company’s 2026 Proxy Statement for the Annual Meeting. The votes on this proposal were as follows:

For		Against		Abstain		Broker Non-Votes
446,238,170		17,487,326		413,667		79,767,645

4. The stockholders voted to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes on this proposal were as follows:

For		Against		Abstain
535,070,921		6,120,699		2,715,188

There were no broker non-votes for the proposal.

No other matters were considered or voted upon at the meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			OPKO Health, Inc.
Date:	June 18, 2026	By:	/s/ Steven D. Rubin
		Name:	Steven D. Rubin
		Title:	Executive Vice President - Administration

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB